Antibody-drug conjugates to treat gastric cancer

被引：11
|
作者：
Koganemaru, Shigehiro [1 ]
Shitara, Kohei [1 ,2 ]
机构：
[1] Natl Canc Ctr Hosp East, Dept Expt Therapeut, Kashiwa, Chiba 2778577, Japan
[2] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan
来源：
EXPERT OPINION ON BIOLOGICAL THERAPY | 2021年 / 21卷 / 07期
关键词：
Antibody-drug conjugate; gastric cancer; translational research; armed antibody; TRASTUZUMAB EMTANSINE; HER2-TARGETING ADC; ADVANCED BREAST; OPEN-LABEL; PRECLINICAL PROFILE; BRENTUXIMAB VEDOTIN; GENE AMPLIFICATION; ANTITUMOR-ACTIVITY; PHASE-II; CAPECITABINE;
D O I：
10.1080/14712598.2020.1802423
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Introduction Despite new treatment options, the long-term prognosis of recurrent or inoperable gastric cancer remains poor. Antibody-drug conjugates (ADCs) are a new class of drugs and have shown promising results in clinical trials. Areas covered This review focuses on recent clinical findings and development of ADCs for gastric cancer, and summarizes the relevant resistance mechanisms or future directions of ADCs. Expert opinion Novel HER2-ADCs have led to breakthrough results forHER2(+)gastric cancer; however, several questions remain, especially in clinical settings. Translational research to elucidate ADCs' mechanisms of action or resistance will lead to more sophisticated use of ADCs and combination strategies.
引用
收藏
页码：923 / 930
页数：8
相关论文
共 50 条
  • [41] Antibody-drug conjugates in HER2-positive breast cancer
    Li, Lixi
    Zhang, Di
    Liu, Binliang
    Lv, Dan
    Zhai, Jingtong
    Guan, Xiuwen
    Yi, Zongbi
    Ma, Fei
    CHINESE MEDICAL JOURNAL, 2022, 135 (03) : 261 - 267
  • [42] Nanoparticle innovations in targeted cancer therapy: advancements in antibody-drug conjugates
    Abdelhamid, Muhammad Sami
    Wadan, Al-Hassan Soliman
    Saad, Hager Adel
    El-Dakroury, Walaa A.
    Hageen, Ahmed W.
    Mohammed, Deyaa H.
    Mourad, Sohaila
    Mohammed, Osama A.
    Abdel-Reheim, Mustafa Ahmed
    Doghish, Ahmed S.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2025, : 6369 - 6389
  • [43] Antibody-Drug Conjugates and Their Potential in the Treatment of Patients with Biliary Tract Cancer
    Alexander, Shaun
    Aleem, Umair
    Jacobs, Timothy
    Frizziero, Melissa
    Foy, Victoria
    Hubner, Richard A.
    McNamara, Mairead G.
    CANCERS, 2024, 16 (19)
  • [44] Antibody-drug conjugates: the new generation of biotechnological therapies against cancer
    Melgarejo-Rubio, Guadalupe
    Perez-Tapia, Sonia M.
    Medina-Rivero, Emilio
    Velasco-Velazquez, Marco A.
    GACETA MEDICA DE MEXICO, 2020, 156 (03): : 228 - 235
  • [45] Antibody-Drug Conjugates
    Kumar, Amit
    White, Jason
    Christie, R. James
    Dimasi, Nazzareno
    Gao, Changshou
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 50: PLATFORM TECHNOLOGIES IN DRUG DISCOVERY AND VALIDATION, 2017, 50 : 441 - 480
  • [46] Antibody-drug conjugates: targeted drug delivery for cancer
    Alley, Stephen C.
    Okeley, Nicole M.
    Senter, Peter D.
    CURRENT OPINION IN CHEMICAL BIOLOGY, 2010, 14 (04) : 529 - 537
  • [47] Antibody-drug conjugates for the treatment of ovarian cancer
    Calo, Corinne A.
    O'Malley, David M.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 875 - 887
  • [48] Antibody-Drug Conjugates for Targeted Cancer Therapy
    Goldmacher, Victor S.
    Chittenden, Thomas
    Chari, Ravi V. J.
    Kovtun, Yelena V.
    Lambert, John M.
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 47, 2012, 47 : 349 - 366
  • [49] Evaluating the safety of antibody-drug conjugates in lung cancer: A systematic review and meta-analysis
    He, Qi
    Jiang, Lin
    Xu, Yan
    Wang, Mengzhao
    LUNG CANCER, 2025, 201
  • [50] Antibody-drug conjugates, cancer immunotherapy, and metronomic chemotherapy as novel approaches in cancer management
    Sarangi, Sudhir Chandra
    Sopory, Pranav
    Pattnaik, Soumya Sucharita
    Reeta, K. H.
    INDIAN JOURNAL OF PHARMACOLOGY, 2020, 52 (05) : 402 - 413
12345